Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elidel Labeling (Clarification)

This article was originally published in The Pink Sheet Daily

Executive Summary

An Oct. 18 1story in "The Pink Sheet" DAILY on declining sales for Novartis' eczema treatment Elidel (pimecrolimus) did not describe with sufficient clarity the status of discussions between the firm and FDA on labeling changes

You may also be interested in...

Elidel Sales Fall In Q3 On Fewer U.S. Prescriptions, Novartis Says

Sales of Novartis' eczema treatment Elidel (pimecrolimus) fell 36% to $53 mil. in the third quarter on fewer U.S. prescriptions, Novartis reported Oct. 18

Novartis' Elidel, Fujisawa's Protopic To Add "Black Box" On Cancer Risk

Novartis expects labeling negotiations will begin within the next few weeks and says a "black box" is unjustified. A medication guide will also be required for the eczema treatments, FDA says.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts